REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Peptide Library

Matrixyl

Palmitoyl Pentapeptide-4 / Pal-KTTKS

Beauty & Skincare

Matrixyl (Palmitoyl Pentapeptide-4, also known as pal-KTTKS) is a cosmetic peptide consisting of a palmitoyl group attached to the pentapeptide lysine-threonine-threonine-lysine-serine, designed to stimulate collagen and extracellular matrix production in dermal fibroblasts. It was developed by Sederma and is one of the most extensively studied and commercially successful topical anti-aging peptides. Matrixyl functions as a matrikine, mimicking the activity of collagen breakdown fragments to signal fibroblasts to produce new collagen, fibronectin, and glycosaminoglycans.

Mechanism of Action

Lipopeptide consisting of a palmitoyl group linked to the pentapeptide KTTKS (a collagen I fragment). Acts as a matrikine, signaling fibroblasts to increase collagen I, III, and IV synthesis, fibronectin production, and hyaluronic acid production via TGF-beta pathway activation.

Research Protocols

For research purposes only. Not medical advice.

Topical application at 2-8% concentration in serums. Applied twice daily. Synergistic with retinol and vitamin C. Results visible after 8-12 weeks of consistent use. Not injected.

Research Notes

Clinical Research Status

Matrixyl has been the subject of multiple clinical studies demonstrating measurable anti-wrinkle efficacy when applied topically at concentrations of 2-5% in appropriate formulations. Double-blind placebo-controlled trials have shown statistically significant improvements in wrinkle depth, skin roughness, and overall photoaging scores after 2-4 months of regular application. It is widely incorporated into commercial skincare products and is recognized by dermatologists as one of the more evidence-based cosmetic peptides available.

Key Published Findings

In vitro studies demonstrate that Matrixyl stimulates collagen I synthesis by up to 350% and collagen IV synthesis by up to 200% in human fibroblast cultures at relevant concentrations. Clinical measurements using profilometry show wrinkle depth reduction of up to 36% after 4 months of twice-daily application in controlled studies. The palmitic acid chain enhances skin penetration and cell membrane interaction compared to the naked KTTKS peptide, which showed limited bioavailability without the lipophilic modification.

Safety Profile

Matrixyl has an excellent safety profile with no reported systemic side effects, sensitization, or phototoxicity in clinical testing, consistent with its topical application and local mechanism of action. Skin irritation is extremely rare and typically associated with other formulation ingredients rather than the peptide itself. It is considered safe for use during pregnancy and lactation at cosmetic concentrations, though formal reproductive toxicology studies have not been conducted.

Comparison to Related Compounds

Matrixyl 3000 is a newer generation product combining Matrixyl (pal-KTTKS) with palmitoyl tripeptide-1 for enhanced synergistic collagen stimulation through complementary pathways. Compared to retinoids, Matrixyl provides collagen stimulation without the associated irritation, photosensitivity, or retinization period, though efficacy is generally considered more modest. Argireline (acetyl hexapeptide-3) works through an entirely different mechanism (neuromuscular modulation) and is complementary rather than competitive with Matrixyl in anti-aging formulations.

Community Observations

Skincare enthusiasts consider Matrixyl one of the best-supported peptides for anti-aging, often incorporated into daily serums alongside vitamin C, niacinamide, and hyaluronic acid. Results are typically reported as gradual improvements in skin texture and fine line appearance over 2-3 months of consistent use. The peptide is available in numerous commercial products ranging from drugstore to luxury price points, with concentration and formulation quality varying significantly across brands.

Half Life

N/A (topical)

Reconstitution

N/A (topical formulation)

Storage

Lyophilized

Room temperature. Stable in cosmetic formulations.

Reconstituted

Stable in formulation. Protect from excessive heat.

US Legal Status

Cosmetic ingredient (unregulated)

Also Known As

Palmitoyl Pentapeptide-4Pal-KTTKS

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer